References
- Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011;18:1172–7
- Gambacciani M, Ciaponi M, Genazzani AR. The HRT misuse and osteoporosis epidemic: a possible future scenario. Climacteric 2007;10:273–5
- Gambacciani M, Genazzani AR. The Xmas present for women's health: a strike to osteoporosis prevention. Maturitas 2004;48: 9–11
- Genazzani AR, Gambacciani M, Schneider HP, Christiansen C; International Menopause Society Expert Workshop. Postmenopausal osteoporosis: therapeutic options. Climacteric 2005;8:99–109
- Sturdee DW, Pines A, on behalf of the International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302–20
- Santen RJ, Allred DC, Ardoin SP, . Postmenopausal hormone therapy: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab 2010;95(Suppl 1):S1–66
- Lees B, Stevenson JC. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17β and dydrogesterone. Osteoporos Int 2001;12:251–8
- Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. J Am Med Assoc 2002;287:2668–76
- Ettinger B, Ensrud KE, Wallace R, . Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443–51
- Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/ conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045–52